Search

Your search keyword '"Velchev, Vasil"' showing total 41 results
Start Over Author "Velchev, Vasil"

Refine your results

more »

more »

more »

more »
41 results on '"Velchev, Vasil"'

1. Impact of Medication Nonadherence in a Clinical Trial of Dual Antiplatelet Therapy

Author

Valgimigli, Marco, Frigoli, Enrico, Vranckx, Pascal, Ozaki, Yukio, Morice, Marie-Claude, Chevalier, Bernard, Onuma, Yoshinobu, Windecker, Stephan, Delorme, Laurent, Kala, Petr, Kedev, Sasko, Abhaichand, Rajpal K., Velchev, Vasil, Dewilde, Willem, Podolec, Jakub, Leibundgut, Gregor, Topic, Dragan, Schultz, Carl, Stankovic, Goran, Lee, Astin, Johnson, Thomas, Tonino, Pim A.L., Klotzka, Aneta, Lesiak, Maciej, Lopes, Renato D., Smits, Pieter C., and Heg, Dik

Published
2022
Full Text
View/download PDF

2. Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥24 h

Author

Becher, Nina, Toennis, Tobias, Bertaglia, Emanuele, Blomström-Lundqvist, Carina, Brandes, Axel, Cabanelas, Nuno, Calvert, Melanie, Camm, A. John, Chlouverakis, Gregory, Dan, Gheorghe-Andrei, Dichtl, Wolfgang, Diener, Hans Christoph, Fierenz, Alexander, Goette, Andreas, de Groot, Joris R., Hermans, Astrid N. L., Lip, Gregory Y. H., Lubinski, Andrzej, Marijon, Eloi, Merkely, Bela, Mont, Lluis, Ozga, Ann-Kathrin, Rajappan, Kim, Sarkozy, Andrea, Scherr, Daniel, Schnabel, Renate B., Schotten, Ulrich, Sehner, Susanne, Simantirakis, Emmanuel, Vardas, Panos, Velchev, Vasil, Wichterle, Dan, Zapf, Antonia, Kirchhof, Paulus, Becher, Nina, Toennis, Tobias, Bertaglia, Emanuele, Blomström-Lundqvist, Carina, Brandes, Axel, Cabanelas, Nuno, Calvert, Melanie, Camm, A. John, Chlouverakis, Gregory, Dan, Gheorghe-Andrei, Dichtl, Wolfgang, Diener, Hans Christoph, Fierenz, Alexander, Goette, Andreas, de Groot, Joris R., Hermans, Astrid N. L., Lip, Gregory Y. H., Lubinski, Andrzej, Marijon, Eloi, Merkely, Bela, Mont, Lluis, Ozga, Ann-Kathrin, Rajappan, Kim, Sarkozy, Andrea, Scherr, Daniel, Schnabel, Renate B., Schotten, Ulrich, Sehner, Susanne, Simantirakis, Emmanuel, Vardas, Panos, Velchev, Vasil, Wichterle, Dan, Zapf, Antonia, and Kirchhof, Paulus

Abstract

Background and Aims Patients with long atrial high-rate episodes (AHREs) >= 24 h and stroke risk factors are often treated with anticoagulation for stroke prevention. Anticoagulation has never been compared with no anticoagulation in these patients. Methods This secondary pre-specified analysis of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High-rate episodes (NOAH-AFNET 6) trial examined interactions between AHRE duration at baseline and anticoagulation with edoxaban compared with placebo in patients with AHRE and stroke risk factors. The primary efficacy outcome was a composite of stroke, systemic embolism, or cardiovascular death. The safety outcome was a composite of major bleeding and death. Key secondary outcomes were components of these outcomes and electrocardiogram (ECG)-diagnosed atrial fibrillation. Results Median follow-up of 2389 patients with core lab-verified AHRE was 1.8 years. AHRE >= 24 h were present at baseline in 259/2389 patients (11%, 78 +/- 7 years old, 28% women, CHA2DS2-VASc 4). Clinical characteristics were not different from patients with shorter AHRE. The primary outcome occurred in 9/132 patients with AHRE >= 24 h (4.3%/patient-year, 2 strokes) treated with anticoagulation and in 14/127 patients treated with placebo (6.9%/patient-year, 2 strokes). Atrial high-rate episode duration did not interact with the efficacy (P-interaction = .65) or safety (P-interaction = .98) of anticoagulation. Analyses including AHRE as a continuous parameter confirmed this. Patients with AHRE >= 24 h developed more ECG-diagnosed atrial fibrillation (17.0%/patient-year) than patients with shorter AHRE (8.2%/patient-year; P < .001). Conclusions This hypothesis-generating analysis does not find an interaction between AHRE duration and anticoagulation therapy in patients with device-detected AHRE and stroke risk factors. Further research is needed to identify patients with long AHRE at high stroke risk.

Published
2024
Full Text
View/download PDF

3. Anticoagulation with edoxaban in patients with long Atrial High-Rate Episodes ≥24 hours

Author

Becher, Nina, primary, Toennis, Tobias, additional, Bertaglia, Emanuele, additional, Blomström-Lundqvist, Carina, additional, Brandes, Axel, additional, Cabanelas, Nuno, additional, Calvert, Melanie, additional, Camm, A John, additional, Chlouverakis, Gregory, additional, Dan, Gheorghe-Andrei, additional, Dichtl, Wolfgang, additional, Diener, Hans Christoph, additional, Fierenz, Alexander, additional, Goette, Andreas, additional, de Groot, Joris R, additional, Hermans, Astrid N L, additional, Lip, Gregory Y H, additional, Lubinski, Andrzej, additional, Marijon, Eloi, additional, Merkely, Béla, additional, Mont, Lluís, additional, Ozga, Ann-Kathrin, additional, Rajappan, Kim, additional, Sarkozy, Andrea, additional, Scherr, Daniel, additional, Schnabel, Renate B, additional, Schotten, Ulrich, additional, Sehner, Susanne, additional, Simantirakis, Emmanuel, additional, Vardas, Panos, additional, Velchev, Vasil, additional, Wichterle, Dan, additional, Zapf, Antonia, additional, and Kirchhof, Paulus, additional

Published
2023
Full Text
View/download PDF

4. Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes

Author

Kirchhof, Paulus, primary, Toennis, Tobias, additional, Goette, Andreas, additional, Camm, A. John, additional, Diener, Hans Christoph, additional, Becher, Nina, additional, Bertaglia, Emanuele, additional, Blomstrom Lundqvist, Carina, additional, Borlich, Martin, additional, Brandes, Axel, additional, Cabanelas, Nuno, additional, Calvert, Melanie, additional, Chlouverakis, Gregory, additional, Dan, Gheorghe-Andrei, additional, de Groot, Joris R., additional, Dichtl, Wolfgang, additional, Kravchuk, Borys, additional, Lubiński, Andrzej, additional, Marijon, Eloi, additional, Merkely, Béla, additional, Mont, Lluís, additional, Ozga, Ann-Kathrin, additional, Rajappan, Kim, additional, Sarkozy, Andrea, additional, Scherr, Daniel, additional, Sznajder, Rafał, additional, Velchev, Vasil, additional, Wichterle, Dan, additional, Sehner, Susanne, additional, Simantirakis, Emmanuel, additional, Lip, Gregory Y.H., additional, Vardas, Panos, additional, Schotten, Ulrich, additional, and Zapf, Antonia, additional

Published
2023
Full Text
View/download PDF

5. The influence of atrial high-rate episodes on stroke and cardiovascular death: an update

Author

Toennis, Tobias, primary, Bertaglia, Emanuele, additional, Brandes, Axel, additional, Dichtl, Wolfgang, additional, Fluschnik, Nina, additional, de Groot, Joris R, additional, Marijon, Eloi, additional, Mont, Lluis, additional, Lundqvist, Carina Blomström, additional, Cabanelas, Nuno, additional, Dan, G Andrei, additional, Lubinski, Andrzej, additional, Merkely, Béla, additional, Rajappan, Kim, additional, Sarkozy, Andrea, additional, Velchev, Vasil, additional, Wichterle, Dan, additional, and Kirchhof, Paulus, additional

Published
2023
Full Text
View/download PDF

8. The influence of atrial high-rate episodes on stroke and cardiovascular death : an update

Author

Toennis, Tobias, Bertaglia, Emanuele, Brandes, Axel, Dichtl, Wolfgang, Fluschnik, Nina, de Groot, Joris R., Marijon, Eloi, Mont, Lluis, Lundqvist, Carina Blomström, Cabanelas, Nuno, Dan, G. Andrei, Lubinski, Andrzej, Merkely, Bela, Rajappan, Kim, Sarkozy, Andrea, Velchev, Vasil, Wichterle, Dan, Kirchhof, Paulus, Toennis, Tobias, Bertaglia, Emanuele, Brandes, Axel, Dichtl, Wolfgang, Fluschnik, Nina, de Groot, Joris R., Marijon, Eloi, Mont, Lluis, Lundqvist, Carina Blomström, Cabanelas, Nuno, Dan, G. Andrei, Lubinski, Andrzej, Merkely, Bela, Rajappan, Kim, Sarkozy, Andrea, Velchev, Vasil, Wichterle, Dan, and Kirchhof, Paulus

Abstract

Atrial high-rate episodes (AHRE) are atrial tachyarrhythmias detected by continuous rhythm monitoring by pacemakers, defibrillators, or implantable cardiac monitors. Atrial high-rate episodes occur in 10-30% of elderly patients without atrial fibrillation. However, it remains unclear whether the presence of these arrhythmias has therapeutic consequences. The presence of AHRE increases the risk of stroke compared with patients without AHRE. Oral anticoagulation would have the potential to reduce the risk of stroke in patients with AHRE but is also associated with a rate of major bleeding of & SIM;2%/year. The stroke rate in patients with AHRE appears to be lower than the stroke rate in patients with atrial fibrillation. Wearables like smart-watches will increase the absolute number of patients in whom atrial arrhythmias are detected. It remains unclear whether anticoagulation is effective and, equally important, safe in patients with AHRE. Two randomized clinical trials, NOAH-AFNET6 and ARTESiA, are expected to report soon. They will provide much-needed information on the efficacy and safety of oral anticoagulation in patients with AHRE.

Published
2023
Full Text
View/download PDF

10. Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug‐Eluting Stent Implantation: Per‐Protocol Analysis of the GLOBAL LEADERS Trial

Author

Gragnano, Felice, primary, Zwahlen, Marcel, additional, Vranckx, Pascal, additional, Heg, Dik, additional, Schmidlin, Kurt, additional, Hamm, Christian, additional, Steg, Philippe Gabriel, additional, Gargiulo, Giuseppe, additional, McFadden, Eugene P., additional, Onuma, Yoshinobu, additional, Chichareon, Ply, additional, Benit, Edouard, additional, Möllmann, Helge, additional, Janssens, Luc, additional, Leonardi, Sergio, additional, Zurakowski, Aleksander, additional, Arrivi, Alessio, additional, Van Geuns, Robert Jan, additional, Huber, Kurt, additional, Slagboom, Ton, additional, Calabrò, Paolo, additional, Serruys, Patrick W., additional, Jüni, Peter, additional, Valgimigli, Marco, additional, Windecker, Stephan, additional, Abdellaoui, Mohamed, additional, Adlam, David, additional, Akin, Ibrahim, additional, Gonzalez‐Trevilla, Agustin Albarran, additional, Almeida, Manuel, additional, Neto, Pedro Alves Lemos, additional, Aminian, Adel, additional, Anderson, Richard, additional, Andreae, Rick, additional, Angioi, Michael, additional, Asano, Taku, additional, Barbato, Emanuele, additional, Barlis, Peter, additional, Barraud, Pascal, additional, Bertrand, Olivier, additional, Beygui, Farzin, additional, Bolognese, Leonardo, additional, Botelho, Roberto, additional, Bouwman, Coby, additional, Bressers, Marco, additional, Brunel, Philippe, additional, Buszman, Pawel, additional, Buysschaert, Ian, additional, da Silva, Pedro Canas, additional, Carrie, Didier, additional, Cequier, Angel, additional, Chang, Chun Chin, additional, Chowdhary, Saqib, additional, Collet, Carlos, additional, Colombo, Antonio, additional, Cotton, James, additional, Ferreira, Rui Cruz, additional, Curello, Salvatore, additional, Curzen, Nick, additional, de Bot, Judith, additional, de Vreede, Tone, additional, Karth, Georg Delle, additional, Dijksma, Lynn, additional, Dominici, Marcello, additional, Édes, István, additional, Eeckhout, Eric, additional, Eitel, Ingo, additional, Faluközy, József, additional, Fath‐Ordoubadi, Farzin, additional, Ferrario, Maurizio, additional, Fontos, Geza, additional, Diaz, Jose Francisco, additional, Quintella, Edgard Freitas, additional, Frey, Bernhard, additional, Friedrich, Guy, additional, Galasko, Gavin, additional, Galuszka, Grzegorz, additional, Ribeiro, Vasco Gama, additional, Garg, Scot, additional, Geisler, Tobias, additional, Gelev, Valeri, additional, Ghandilyan, Art, additional, Goicolea, Javier, additional, Gori, Tommaso, additional, Gragnano, Felice, additional, Guimarães, Ana, additional, Haude, Michael, additional, Heijke, Pieter, additional, Antolin, Rosa Ana Hernández, additional, Hildick‐Smith, David, additional, Hillen, Dorien, additional, Hoekman, Ina, additional, Hofma, Sjoerd, additional, Holmvang, Lene, additional, Hoole, Stephen, additional, Horváth, Iván, additional, Hugense, Annemarie, additional, Ibrahim, Karim, additional, Iñiguez, Andres, additional, Isaaz, Karl, additional, Jambrik, Zoltán, additional, Jasionowicz, Pawel, additional, Jonk, Judith, additional, Jung, Werner, additional, Katagiri, Yuki, additional, Kogame, Norihiro, additional, Koh, Tian Hai, additional, Koning, René, additional, Konteva, Mariana, additional, Kőszegi, Zsolt, additional, Krackhardt, Florian, additional, Kreuger, Yvonne, additional, Kukreja, Neville, additional, Ladan, Boudijn, additional, Lantelme, Pierre, additional, Leandro, Sergio, additional, Leibundgut, Gregor, additional, Liebetrau, Christoph, additional, Lindeboom, Wietze, additional, Miguel, Carlos Macaya, additional, Mach, François, additional, Magro, Michael, additional, Maillard, Luc, additional, Manavifar, Negar, additional, Mauri, Laura, additional, McFadden, Eugene, additional, Merkely, Bela, additional, Miyazaki, Yosuke, additional, Młodziankowski, Adam, additional, Moccetti, Tiziano, additional, Modolo, Rodrigo, additional, Möllman, Helge, additional, Morelle, Jean‐François, additional, Moschovitis, Aris, additional, Ottesen, Michael Munndt, additional, Muurling, Martin, additional, Naber, Christoph Kurt, additional, Neumann, Franz‐Josef, additional, Oldroyd, Keith, additional, Ong, Paul, additional, Palsrok, Sanne, additional, Petrov, Ivo, additional, Plante, Sylvain, additional, Prokopczuk, Janusz, additional, Rademaker‐Havinga, Tessa, additional, Raffel, Christopher, additional, Rensing, Benno, additional, Roffi, Marco, additional, Royaards, Kees‐Jan, additional, Sabate, Manel, additional, Schächinger, Volker, additional, Seidler, Tim, additional, Peñaranda, Antonio Serra, additional, Serruys, Patrick, additional, Sikarulidze, Lali, additional, Soliman, Osama I, additional, Sousa, Amanda, additional, Spitzer, Ernest, additional, Stables, Rod, additional, Steg, Gabriel, additional, Steinwender, Clemens, additional, Subkovas, Eduardas, additional, Suryapranata, Harry, additional, Takahashi, Kuniaki, additional, Talwar, Suneel, additional, Teiger, Emmanuel, additional, Weele, Addy Ter, additional, Teurlings, Eva, additional, Thury, Attila, additional, Tijssen, Jan, additional, Tonev, Gincho, additional, Trendafilova‐Lazarova, Diana, additional, Tumscitz, Carlo, additional, Umans, Victor, additional, Ungi, Imre, additional, Valkov, Veselin, additional, van der Harst, Pim, additional, van Geuns, Robert Jan, additional, van Meijeren, Cokky, additional, Vassilev, Dobrin, additional, Velchev, Vasil, additional, Velthuizen, Esther, additional, Verheugt, Freek, additional, Vlcek, Natalia, additional, Dahl, Jürgen Vom, additional, Vrolix, Mathias, additional, Walsh, Simon, additional, Werner, Nikos, additional, Witsenburg, Maarten, additional, Zaman, Azfar, additional, Żmudka, Krzysztof, additional, Zrenner, Bernhard, additional, and Zweiker, Robert, additional

Published
2022
Full Text
View/download PDF

12. Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study

Author

Zabel, Markus, Willems, Rik, Lubinski, Andrzej, Bauer, Axel, Brugada, Josep, Conen, David, Flevari, Panagiota, Hasenfuß, Gerd, Svetlosak, Martin, Huikuri, Heikki V, Malik, Marek, Pavlović, Nikola, Schmidt, Georg, Sritharan, Rajevaa, Schlögl, Simon, Szavits-Nossan, Janko, Traykov, Vassil, Tuinenburg, Anton E, Willich, Stefan N, Harden, Markus, Friede, Tim, Svendsen, Jesper Hastrup, Sticherling, Christian, Merkely, Béla, Perge, Peter, Sallo, Zoltan, Szeplaki, Gabor, Szegedi, Nandor, Nagy, Klaudia Vivien, Lüthje, Lars, Sritharan, R, Haarmann, Helge, Bergau, Leonard, Seegers, Joachim, Munoz- Exposito, Pascal, Tichelbäcker, Tobias, Kirova, Aleksandra, Hnatkova, Katerina, Vos, Marc A, Reinhold, Thomas, Vandenberk, Bert, Klinika, Magdalena, Rotkvić, L, Flevari, Panayota, Katsimardos, Andreas, Katsaras, Dimitrios, Hatala, Robert, Kuczejko, Tomasz, Hansen, Jim, Manola, Šime, Vinter, Ozren, Benko, Ivica, Tuinenburg, Anton, Sprenkeler, David, Smoczynska, A, Vos, M A, Meyer-Zürn, Christine, Eick, Christian, Arbelo, Elena, Kaliska, Gabriela, Martinek, Jozef, Dommasch, Michael, Steger, Alexander, Kääb, Stefan, Sinner, Moritz F, Rizas, Konstantinos D, Hamm, Wolfgang, Traykov, V, Cygankiewicz, Iwona, Ptaszyński, Pawel, Kaczmarek, K, Poddebska, I, Iovev, Svetoslav, Novotný, Tomáš, Kozak, Milan, Huikuri, Heikki, Kenttä, Tuomas, Pelli, Ari, Kasprzak, Jaroslaw D, Qavoq, Dariusz, Brusich, Sandro, Avdovic, Ervin, Klasan, Marina, Galuszka, Jan, Taborsky, Milos, Velchev, Vasil, Dissmann, Rüdiger, Shalganov, T, Guzik, P, Krauze, T, Bimmel, Dieter, Lieberz, Christiane, Ludwigsburg, Klinikum, Stefanow, Stefan, Rüb, Norman, Wolpert, Christian, Meier, Lars S, Behrens, Steffen, Jurisic, Zrinka, Braunschweig, Frieder, Blaschke, Florian, Pieske, Burkert, Bakotic, Zoran, Anic, Ante, Weiden, Klinikum, Schwinger, Robert H G, Platonov, Pyotr, Grönefeld, Gerian, Klingenheben, Thomas, and EU-CERT-ICD Study Investigators

Subjects
medicine.medical_specialty, medicine.medical_treatment, Implantable cardioverter-defibrillator, Risk factors, Mortality, Sudden cardiac death, 030204 cardiovascular system & hematology, Ventricular Function, Left, Cohort Studies, EU-CERT-ICD Study Investigators, 03 medical and health sciences, 0302 clinical medicine, Clinical Research, Internal medicine, medicine, Clinical endpoint, Humans, AcademicSubjects/MED00200, Prospective Studies, 030212 general & internal medicine, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine, 1102 Cardiorespiratory Medicine and Haematology, Aged, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina, Heart Failure, Ejection fraction, Ischemic cardiomyopathy, business.industry, Hazard ratio, Stroke Volume, 1103 Clinical Sciences, Dilated cardiomyopathy, medicine.disease, Confidence interval, Defibrillators, Implantable, 3. Good health, Europe, Primary Prevention, Death, Sudden, Cardiac, Treatment Outcome, Cardiovascular System & Hematology, Implantable cardioverter-defibrillator, Risk factors, Mortality, Sudden cardiac death, Cardiology and Cardiovascular Medicine, business, Cohort study
Abstract

Aims The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter-Defibrillators (EU-CERT-ICD), a prospective investigator-initiated, controlled cohort study, was conducted in 44 centres and 15 European countries. It aimed to assess current clinical effectiveness of primary prevention ICD therapy. Methods and results We recruited 2327 patients with ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and guideline indications for prophylactic ICD implantation. Primary endpoint was all-cause mortality. Clinical characteristics, medications, resting, and 12-lead Holter electrocardiograms (ECGs) were documented at enrolment baseline. Baseline and follow-up (FU) data from 2247 patients were analysable, 1516 patients before first ICD implantation (ICD group) and 731 patients without ICD serving as controls. Multivariable models and propensity scoring for adjustment were used to compare the two groups for mortality. During mean FU of 2.4 ± 1.1 years, 342 deaths occurred (6.3%/years annualized mortality, 5.6%/years in the ICD group vs. 9.2%/years in controls), favouring ICD treatment [unadjusted hazard ratio (HR) 0.682, 95% confidence interval (CI) 0.537–0.865, P = 0.0016]. Multivariable mortality predictors included age, left ventricular ejection fraction (LVEF), New York Heart Association class Conclusion In contemporary ICM/DCM patients (LVEF ≤35%, narrow QRS), primary prophylactic ICD treatment was associated with a 27% lower mortality after adjustment. There appear to be patients with less survival advantage, such as older patients or diabetics.

Published
2020
Full Text
View/download PDF

17. Q waves are the strongest electrocardiographic variable associated with primary prophylactic implantable cardioverter-defibrillator benefit: a prospective multicentre study

Author

Pelli, Ari, Junttila, M Juhani, Kenttä, Tuomas V, Schlögl, Simon, Zabel, Markus, Malik, Marek, Reichlin, Tobias, Willems, Rik, Vos, Marc A, Harden, Markus, Friede, Tim, Sticherling, Christian, Huikuri, Heikki V, Arbelo, Elena, Bauer, Axel, Braunschweig, Frieder, Brugada, Josep, Conen, David, Cygankiewicz, Iwona, Dommasch, Michael, Eick, Christian, Flevari, Panagiota, Galuszka, Jan, Hansen, Jim, Hatala, Robert, Hnatkova, Katerina, Junttila, Juhani M, Kääb, Stefan, Kaliska, Gabriela, Kasprzak, Jaroslaw D, Katsimardos, Andreas, Kozak, Milan, Kuczejko, Tomasz, Lubinski, Andrzej, Martinek, Jozef, Merkely, Béla, Novotný, Tomáš, Perge, Peter, Pieske, Burkert, Platonov, Pyotr, Ptaczyński, Pawel, Qavoq, Dariusz, Rotkvić, L, Sallo, Zoltan, Schmidt, Georg, Sinner, Moritz, Sritharan, Rajeeva, Stefanow, Stefan, Svendsen, Jesper Hastrup, Svetlosak, Martin, Szavits-Nossan, Janko, Taborsky, Milos, Tuinenburg, Anton, Vandenberk, Bert, Willich, Stefan N, Wolpert, Christian, Anic, Ante, Bakotic, Zoran, Behrens, Steffen, Bimmel, Dieter, Brusich, Sandro, Dissmann, Rüdiger, Grönefeld, Gerian, Guzik, Przemyzlav, Iovev, Svetoslav, Jurisic, Zrinka, Klingenheben, Thomas, Pavlović, Nikola, Seegers, Joachim, Schwinger, Robert H G, Shalganov, Tchavdar, Traykov, Vassil, Velchev, Vasil, and the EU-CERT-ICD Study Investigators

Subjects
QT interval, medicine.medical_specialty, medicine.medical_treatment, Population, 610 Medicine & health, Heart failure, Benefit, 030204 cardiovascular system & hematology, Implantable cardioverter-defibrillator, 03 medical and health sciences, Electrocardiography, 0302 clinical medicine, Risk Factors, Physiology (medical), Internal medicine, Medicine, Humans, 030212 general & internal medicine, Prospective Studies, Mortality, education, Pathological, education.field_of_study, Primary prevention, business.industry, Incidence (epidemiology), Hazard ratio, Arrhythmias, Cardiac, Appropriate shock, Electrocardiogram, Q wave, medicine.disease, Confidence interval, Defibrillators, Implantable, Primary Prevention, Death, Sudden, Cardiac, Cardiology, Cardiology and Cardiovascular Medicine, business
Abstract

Aim The association of standard 12-lead electrocardiogram (ECG) markers with benefits of the primary prophylactic implantable cardioverter-defibrillator (ICD) has not been determined in the contemporary era. We analysed traditional and novel ECG variables in a large prospective, controlled primary prophylactic ICD population to assess the predictive value of ECG in terms of ICD benefit. Methods and results Electrocardiograms from 1477 ICD patients and 700 control patients (EU-CERT-ICD; non-randomized, controlled, prospective multicentre study; ClinicalTrials.gov Identifier: NCT02064192), who met ICD implantation criteria but did not receive the device, were analysed. The primary outcome was all-cause mortality. In ICD patients, the co-primary outcome of first appropriate shock was used. Mean follow-up time was 2.4 ± 1.1 years to death and 2.3 ± 1.2 years to the first appropriate shock. Pathological Q waves were associated with decreased mortality in ICD patients [hazard ratio (HR) 0.54, 95% confidence interval (CI) 0.35–0.84; P Conclusion Pathological Q waves were a strong ECG predictor of ICD benefit in primary prophylactic ICD patients. Excess mortality among Q wave patients seems to be due to arrhythmic death which can be prevented by ICD.

Published
2021
Full Text
View/download PDF

19. Diagnostic algorithm in transthyretin amyloidosis with cardiomyopathy

Author

Gospodinova, Mariana, Kinova, Elena, Simova, Iana, Yotov, Yoto, Garcheva, Marina, Kirova, Galina, Genova, Kameliya, Todorova, Albena, Sarafov, Stayko, Tournev, Ivailo, Tokmakova, Mariya, and Velchev, Vasil

Subjects
транстиретина амилоидоза, treatment, diagnosis, кардиомиопатия, диагноза, cardiomyopathy, лечение transthyretin amyloidosis
Abstract

Транстиретиновата сърдечна амилоидоза е рестриктивна кардиомиопатия (ATTR-КМП), резултат от извънклетъчно натрупване на неразтворими транстиретинови амилоидни фибрили в миокарда, има прогресиращ ход и е възможен летален изход в рамките на 2-6 години от поставяне на диагнозата. Бива два вида – наследствена и див тип. Данни от последните години показват, че дивият тип АТТР-КМП е относително честа причина за сърдечна недостатъчност със запазена фракция на изтласкване, особено при по-възрастни мъже. В същото време в България, наследствената транстиретинова амилоидоза не е толкова рядка. Диагностицирни са пет различни патологични мутации. Най-разпространена е р.Glu89Gln, като по данни от юни 2019 г има установени 62 несвързани семейства с 117 пациенти и 72 носители. Диагнозата АТТР-КМП често се поставя със закъснение или се пропуска, а нейното ранно диагностициране е изключително важно, тъй като има одобрен медикамент (стабилизатор на транстиретина), който е по-ефикасен приложен в начален стадий на заболяването. Други медикаменти са в клинични изпитания. Диагностицирането на АТТР-КМП е процес, който изисква мултидисциплинарен подход с участието на подготвени специалисти, мултимодална образна диагностика, добре оборудвани хистопатологична и генетична лаборатории. Изграждането на експертни центрове на функционален принцип би могло да допринесе за по-ранното откриване, своевременното лечение и проследяването на пациентите с АТТР-КМП, което съответно да подобри тяхната прогноза. Transthyretin cardiac amyloidosis is a restrictive cardiomyopathy ((ATTR-CM), caused by an extracellular deposition of insoluble amyloid fibrils in the myocardium. It is a life threatening disease with life expectancy of 2 to 6 years after diagnosis. There are two types – hereditary and wild type. Recent data reveal that the wild type ATTR-CM is a common cause of heart failure with preserved ejection fraction, especially in elderly men. Hereditary ATTR amyloidosis is not so rare in Bulgaria. Five different mutations have been diagnosed, the most common being p.Glu89Gln, identified in 62 unrelated families with 117 patients and 72 mutation carriers. ATTR-CM diagnosis is often delayed or even missed, however its early recognition has become very important as a new drug, which is a transthyretin stabilizer is now available and other drugs are under development. Updated knowledge about the clinical presentation, diagnostic algorithm, available and future therapeutic options for ATTR-CM are a prerequisite for an early identification, timely treatment and better prognosis of the affected patients. The diagnosis requires a multidisciplinary approach with the participation of experienced specialists, multimodality imaging, well equipped histopathological and genetic laboratories. Establishing centres of expertise could improve the management of the patients with ATTR-CM.

Published
2020
Full Text
View/download PDF

20. Appropriate Shocks and Mortality in Patients With Versus Without Diabetes With Prophylactic Implantable Cardioverter Defibrillators

Author

Junttila, M. Juhani, Pelli, Ari, Kenttä, Tuomas V., Friede, Tim, Willems, Rik, Bergau, Leonard, Malik, Marek, Vandenberk, Bert, Vos, Marc A., Schmidt, Georg, Merkely, Bela, Lubinski, Andrzej, Svetlosak, Martin, Braunschweig, Frieder, Harden, Markus, Zabel, Markus, Huikuri, Heikki V., Sticherling, Christian, Seegers, Joachim, Hasenfuß, Gerd, Munoz-Exposito, Pascal, Tichelbäcker, Tobias, Kirova, Aleksandra, Schlögl, Simon, Sritharan, Rajevaa, Jörß, Katharina, Macken, Jessica, Misdaq, Misbah, Rudolph, Kornelia, Bauer, Axel, Meyer-Zürn, Christine, Eick, Christian, rechts der Isar, Klinikum, Schmidt, Goerg, Müller, Alexander, Dommasch, Michael, Sinnecker, Daniel, Kääb, Stefan, Sinner, Moritz F., Dissmann, Rüdiger, Burmester, Ute, Behrens, Steffen, Gregor, Martina, Stefanow, Stefan, Rüb, Norman, Wolpert, Christian, Bimmel, Dieter, Lieberz, Christiane, Maier, Lars S., Schwinger, Robert H.G., Blaschke, Florian, Pieske, Burkert, Grönefeld, Gerian, Klein, Gunnar, Gardiwal, Ajmal, Szeplaki, Gabor, Perge, Peter, Szavits Nossan, Janko, Rotkvić, Luka, Pavlovic, Nikola, Manola, Sime, Vinter, Ozren, Benko, Ivica, Brusic, Sandro, Avdovic, Ervin, Klasan, Marina, Bakotic, Zoran, Anic, Ante, Jurisic, Zrinka, Kowalczyk, Emilia, Kucejko, Tomasz, Czechowska, Agnieszka, Wybor, Katarina, Cygankiewicz, Iwona, Ptaszyński, Pawel, Kasprzak, Jaroslaw, Qavoq, Dariusz, Guzik, Przemyslaw, Krauze, Tomasz, Sterlinski, Maciej, Hatala, Robert, Kaliska, Gabriela, Martinek, Jozef, Hastrup Svendsen, Jesper, Thamsborg, Karen, Hansen, Jim, Schloett-Hyldelund, Ida-Maria, Laage-Petersen, Julie, van Soest, Sofie, Flevari, Panayota, Katsaras, Dimitrios, Katsimardos, Andreas, Leftheriotis, Dionyssios, Papangelopoulou, Konstantinia, Varlamos, Charalambos, Traykov, Vassil, Velchev, Vasil, Iovev, Svetoslav, Shalganov, Tchavdar, Conen, David, Giesebart, Sarah, Novotny, Tomas, Kozak, Milan, Taborsky, Milos, Galuszka, Jan, Tuinenburg, Anton E., Wijers, Sofieke, Dunnink, Albert, Sprenkeler, David, Brugada, Josep, Arbelo, Elena, Trucco, Emilce, Vidorreta, Silvia, Kenttä, Tuomas, Huikuri, Pirkko, Koski, Päivi, Karlsson, Helena, Ersgaard, David, Platonov, Pyotr, Klingenheben, Thomas, and EU-CERT-ICD Investigators

Subjects
Male, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Ventricular Function, Left, DISEASE, Sudden cardiac death, Endocrinology, 0302 clinical medicine, Tachycardia, Medicine, FIBROSIS, Advanced and Specialised Nursing, 030212 general & internal medicine, Registries, 11 Medical and Health Sciences, RISK, Electroshock, OUTCOMES, Incidence (epidemiology), Incidence, Hazard ratio, ASSOCIATION, Middle Aged, Implantable cardioverter-defibrillator, 3. Good health, Defibrillators, Implantable, Diabetes and Metabolism, Primary Prevention, PRESERVED EJECTION FRACTION, Cardiology, Female, VENTRICULAR-FIBRILLATION, Life Sciences & Biomedicine, medicine.medical_specialty, 030209 endocrinology & metabolism, Lower risk, Sudden death, 03 medical and health sciences, Endocrinology & Metabolism, Diabetes mellitus, Internal medicine, Journal Article, Internal Medicine, Diabetes Mellitus, Humans, Aged, Retrospective Studies, Advanced and Specialized Nursing, Science & Technology, business.industry, Retrospective cohort study, medicine.disease, Death, Sudden, Cardiac, MYOCARDIAL-INFARCTION, ICD sudden death cardiomyopathy, business, SUDDEN CARDIAC DEATH, Diabetic Angiopathies, Follow-Up Studies
Abstract

OBJECTIVE Diabetes increases the risk of all-cause mortality and sudden cardiac death (SCD). The exact mechanisms leading to sudden death in diabetes are not well known. We compared the incidence of appropriate shocks and mortality in patients with versus without diabetes with a prophylactic implantable cardioverter defibrillator (ICD) included in the retrospective EU-CERT-ICD registry. RESEARCH DESIGN AND METHODS AND RESULTS A total of 3,535 patients from 12 European EU-CERT-ICD centers with a mean age of 63.7 ± 11.2 years (82% males) at the time of ICD implantation were included in the analysis. A total of 995 patients (28%) had a history of diabetes. All patients had an ICD implanted for primary SCD prevention. End points were appropriate shock and all-cause mortality. Mean follow-up time was 3.2 ± 2.3 years. Diabetes was associated with a lower risk of appropriate shocks (adjusted hazard ratio [HR] 0.77 [95% CI 0.62–0.96], P = 0.02). However, patients with diabetes had significantly higher mortality (adjusted HR 1.30 [95% CI 1.11–1.53], P = 0.001). CONCLUSIONS All-cause mortality is higher in patients with diabetes than in patients without diabetes with primary prophylactic ICDs. Subsequently, patients with diabetes have a lower incidence of appropriate ICD shocks, indicating that the excess mortality might not be caused primarily by ventricular tachyarrhythmias. These findings suggest a limitation of the potential of prophylactic ICD therapy to improve survival in patients with diabetes with impaired left ventricular function.

Published
2020

21. And don't forget your anti in-stent stenosis pill! Commentary on 'Factors associated with in-stent stenosis after cerebral aneurysm embolization using a Pipeline embolization device' by Flores-Milan et al.

Author

Sirakov, Alexander, Stoyanov, Nikolay, Velchev, Vasil, and Sirakov, Stanimir

Subjects
INTRACRANIAL aneurysms, RADIOEMBOLIZATION, INTRACRANIAL aneurysm ruptures, STENOSIS, ANGIOGRAPHY, PILLS
Abstract

In their INR study, Flores-Milan et al. present a retrospective single-centre study that aimed to investigate and determine some of the factors associated with in-stent stenosis (ISS) after intracranial aneurysm (IA) embolization using a commercially available flow diverter stent (FD). The retrospective analyses included ruptured and unruptured intracranial aneurysms treated with standalone flow diverter stent implantation or initial coil obliteration with the FD device placed subsequently two weeks after initial treatment. The article's methodology was carefully tailored to demystify the unknown pathophysiological mechanism behind the entity of interest called in-stent stenosis. Study outcomes also included angiographic evaluation of aneurysm occlusion thrombotic and hemorrhagic events. The authors reported excellent technical and clinical results altogether. The achieved angiographic occlusion rates resonate with the current obliteration results reported in the literature. Mortality and morbidity are congruent with previously published results and were 5.3% and 1.1%, respectively. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. Rationale and design of the EU‐CERT‐ICD prospective study: comparative effectiveness of prophylactic ICD implantation

Author

Zabel, Markus, Sticherling, Christian, Willems, Rik, Lubinski, Andrzej, Bauer, Axel, Bergau, Leonard, Braunschweig, Frieder, Brugada, Josep, Brusich, Sandro, Conen, David, Cygankiewicz, Iwona, Flevari, Panagiota, Taborsky, Milos, Hansen, Jim, Hasenfuß, Gerd, Hatala, Robert, Huikuri, Heikki V., Iovev, Svetoslav, Kääb, Stefan, Kaliska, Gabriela, Kasprzak, Jaroslaw D., Lüthje, Lars, Malik, Marek, Novotny, Tomas, Pavlović, Nikola, Schmidt, Georg, Shalganov, Tchavdar, Sritharan, Rajeeva, Schlögl, Simon, Szavits Nossan, Janko, Traykov, Vassil, Tuinenburg, Anton E., Velchev, Vasil, Vos, Marc A., Willich, Stefan N., Friede, Tim, Svendsen, Jesper Hastrup, and Merkely, Béla

Subjects
Cardiomyopathy, Dilated, Study Designs, Risk Assessment, Electrocardiography, Implantable cardioverter defibrillator, Humans, Prospective Studies, Mortality, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina, Study Design, Patient Selection, Corrigenda, Defibrillators, Implantable, Europe, Primary Prevention, Survival Rate, Sudden cardiac death, Death, Sudden, Cardiac, Treatment Outcome, Risk factors, Quality of Life, Corrigendum, Follow-Up Studies
Abstract

AIMS: The clinical effectiveness of primary prevention implantable cardioverter defibrillator (ICD) therapy is under debate. The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators (EU-CERT-ICD) aims to assess its current clinical value. METHODS AND RESULTS: The EU-CERT-ICD is a prospective investigator-initiated non-randomized, controlled, multicentre observational cohort study performed in 44 centres across 15 European Union countries. We will recruit 2250 patients with ischaemic or dilated cardiomyopathy and a guideline indication for primary prophylactic ICD implantation. This sample will include 1500 patients at their first ICD implantation and 750 patients who did not receive a primary prevention ICD despite having an indication for it (non-randomized control group). The primary endpoint is all-cause mortality; the co-primary endpoint in ICD patients is time to first appropriate shock. Secondary endpoints include sudden cardiac death, first inappropriate shock, any ICD shock, arrhythmogenic syncope, revision procedures, quality of life, and cost-effectiveness. At baseline (and prior to ICD implantation if applicable), all patients undergo 12-lead electrocardiogram (ECG) and Holter ECG analysis using multiple advanced methods for risk stratification as well as detailed documentation of clinical characteristics and laboratory values. Genetic biobanking is also organized. As of August 2018, baseline data of 2265 patients are complete. All subjects will be followed for up to 4.5 years. CONCLUSIONS: The EU-CERT-ICD study will provide a necessary update about clinical effectiveness of primary prophylactic ICD implantation. This study also aims for improved risk stratification and patient selection using clinical and ECG risk markers. peerReviewed

Published
2018
Full Text
View/download PDF

23. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

Author

Neumann, Franz Josef, Sechtem, Udo, Banning, Adrian Paul, Bonaros, Nikolaos, Bueno, Héctor, Bugiardini, Raffaele, Chieffo, Alaide, Crea, Filippo, Czerny, Martin, Delgado, Victoria, Dendale, Paul, Knuuti, Juhani, Wijns, William, Flachskampf, Frank Arnold, Gohlke, Helmut, Grove, Erik Lerkevang, James, Stefan, Katritsis, Demosthenes, Landmesser, Ulf, Lettino, Maddalena, Matter, Christian M., Nathoe, Hendrik, Niessner, Alexander, Patrono, Carlo, Petronio, Anna Sonia, Pettersen, Steffen E., Piccolo, Raffaele, Piepoli, Massimo Francesco, Popescu, Bogdan A., Räber, Lorenz, Richter, Dimitrios J., Roffi, Marco, Roithinger, Franz X., Shlyakhto, Evgeny, Sibbing, Dirk, Silber, Sigmund, Simpson, Iain A., Sousa-Uva, Miguel, Vardas, Panos, Witkowski, Adam, Zamorano, Jose Luis, Achenbach, Stephan, Agewall, Stefan, Barbato, Emanuele, Bax, Jeroen J., Capodanno, Davide, Cuisset, Thomas, Deaton, Christi, Dickstein, Kenneth, Edvardsen, Thor, Escaned, Javier, Funck-Brentano, Christian, Gersh, Bernard J., Gilard, Martine, Hasdai, David, Hatala, Robert, Mahfoud, Felix, Masip, Josep, Muneretto, Claudio, Prescott, Eva, Saraste, Antti, Storey, Robert F., Svitil, Pavel, Valgimigli, Marco, Aboyans, Victor, Baigent, Colin, Collet, Jean Philippe, Dean, Veronica, Fitzsimons, Donna, Gale, Christopher P., Grobbee, Diederick E., Halvorsen, Sigrun, Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A., Leclercq, Christophe, Lewis, Basil S., Merkely, Bela, Mueller, Christian, Petersen, Steffen, Touyz, Rhian M., Benkhedda, Salim, Metzler, Bernhard, Sujayeva, Volha, Cosyns, Bernard, Kusljugic, Zumreta, Velchev, Vasil, Panayi, Georgios, Kala, Petr, Haahr-Pedersen, Sune Ammentorp, Kabil, Hamza, Ainla, Tiia, Kaukonen, Tomi, Cayla, Guillaume, Pagava, Zurab, Woehrle, Jochen, Kanakakis, John, Toth, Kalman, Gudnason, Thorarinn, Peace, Aaron, Aronson, Doron, Riccio, Carmine, Elezi, Shpend, Mirrakhimov, Erkin, Hansone, Silvija, Sarkis, Antoine, Babarskiene, Ruta, Beissel, Jean, Cassar Maempel, Andrew J., Revenco, Valeriu, de Grooth, G. J., Pejkov, Hristo, Juliebø, Vibeke, Lipiec, Piotr, Santos, Jose, Chioncel, Ovidiu, Duplyakov, Dmitry, Bertelli, Luca, Dikic, Ana Djordjevic, Studencan, Martin, Bunc, Matjaz, Alfonso, Fernando, Back, Magnus, Zellweger, Michael, Addad, Faouzi, Yildirir, Aylin, Sirenko, Yuriy, Clapp, Brian, Neumann, Franz Josef, Sechtem, Udo, Banning, Adrian Paul, Bonaros, Nikolaos, Bueno, Héctor, Bugiardini, Raffaele, Chieffo, Alaide, Crea, Filippo, Czerny, Martin, Delgado, Victoria, Dendale, Paul, Knuuti, Juhani, Wijns, William, Flachskampf, Frank Arnold, Gohlke, Helmut, Grove, Erik Lerkevang, James, Stefan, Katritsis, Demosthenes, Landmesser, Ulf, Lettino, Maddalena, Matter, Christian M., Nathoe, Hendrik, Niessner, Alexander, Patrono, Carlo, Petronio, Anna Sonia, Pettersen, Steffen E., Piccolo, Raffaele, Piepoli, Massimo Francesco, Popescu, Bogdan A., Räber, Lorenz, Richter, Dimitrios J., Roffi, Marco, Roithinger, Franz X., Shlyakhto, Evgeny, Sibbing, Dirk, Silber, Sigmund, Simpson, Iain A., Sousa-Uva, Miguel, Vardas, Panos, Witkowski, Adam, Zamorano, Jose Luis, Achenbach, Stephan, Agewall, Stefan, Barbato, Emanuele, Bax, Jeroen J., Capodanno, Davide, Cuisset, Thomas, Deaton, Christi, Dickstein, Kenneth, Edvardsen, Thor, Escaned, Javier, Funck-Brentano, Christian, Gersh, Bernard J., Gilard, Martine, Hasdai, David, Hatala, Robert, Mahfoud, Felix, Masip, Josep, Muneretto, Claudio, Prescott, Eva, Saraste, Antti, Storey, Robert F., Svitil, Pavel, Valgimigli, Marco, Aboyans, Victor, Baigent, Colin, Collet, Jean Philippe, Dean, Veronica, Fitzsimons, Donna, Gale, Christopher P., Grobbee, Diederick E., Halvorsen, Sigrun, Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A., Leclercq, Christophe, Lewis, Basil S., Merkely, Bela, Mueller, Christian, Petersen, Steffen, Touyz, Rhian M., Benkhedda, Salim, Metzler, Bernhard, Sujayeva, Volha, Cosyns, Bernard, Kusljugic, Zumreta, Velchev, Vasil, Panayi, Georgios, Kala, Petr, Haahr-Pedersen, Sune Ammentorp, Kabil, Hamza, Ainla, Tiia, Kaukonen, Tomi, Cayla, Guillaume, Pagava, Zurab, Woehrle, Jochen, Kanakakis, John, Toth, Kalman, Gudnason, Thorarinn, Peace, Aaron, Aronson, Doron, Riccio, Carmine, Elezi, Shpend, Mirrakhimov, Erkin, Hansone, Silvija, Sarkis, Antoine, Babarskiene, Ruta, Beissel, Jean, Cassar Maempel, Andrew J., Revenco, Valeriu, de Grooth, G. J., Pejkov, Hristo, Juliebø, Vibeke, Lipiec, Piotr, Santos, Jose, Chioncel, Ovidiu, Duplyakov, Dmitry, Bertelli, Luca, Dikic, Ana Djordjevic, Studencan, Martin, Bunc, Matjaz, Alfonso, Fernando, Back, Magnus, Zellweger, Michael, Addad, Faouzi, Yildirir, Aylin, Sirenko, Yuriy, and Clapp, Brian

Abstract

Coronary artery disease (CAD) is a pathological process characterized by atherosclerotic plaque accumulation in the epicardial arteries, whether obstructive or non-obstructive. This process can be modified by lifestyle adjustments, pharmacological therapies, and invasive interventions designed to achieve disease stabilization or regression. The disease can have long, stable periods but can also become unstable at any time, typically due to an acute atherothrombotic event caused by plaque rupture or erosion. However, the disease is chronic, most often progressive, and hence serious, even in clinically apparently silent periods. The dynamic nature of the CAD process results in various clinical presentations, which can be conveniently categorized as either acute coronary syndromes (ACS) or chronic coronary syndromes (CCS). The Guidelines presented here refer to the management of patients with CCS. The natural history of CCS is illustrated in Figure 1.

Published
2020

25. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries

Author

Widimsky, Petr, Wijns, William, Fajadet, Jean, de Belder, Mark, Knot, Jiri, Aaberge, Lars, Andrikopoulos, George, Baz, Jose Antonio, Betriu, Amadeo, Claeys, Marc, Danchin, Nicholas, Djambazov, Slaveyko, Erne, Paul, Hartikainen, Juha, Huber, Kurt, Kala, Petr, Klinčeva, Milka, Kristensen, Steen Dalby, Ludman, Peter, Ferre, Josephina Mauri, Merkely, Bela, Miličić, Davor, Morais, Joao, Noč, Marko, Opolski, Grzegorz, Ostojić, Miodrag, Radovanovič, Dragana, De Servi, Stefano, Stenestrand, Ulf, Studenčan, Martin, Tubaro, Marco, Vasiljević, Zorana, Weidinger, Franz, Witkowski, Adam, Zeymer, Uwe, Legrand, Victor, Velchev, Vasil, Heiztler, Vjeran Nikolić, Babić, Zdravko, Bergovec, Mijo, Žerjavić, Vlasta Hrabak, Kralj, Verica, Zelizko, Michael, Aschermann, Michael, Jansky, Petr, Tousek, Frantisek, Holm, Frantisek, Junker, Anders, Marandi, Toomas, Gilard, Martine, Blanchard, Didier, Schaechinger, Volker, Gitt, Anselm, Boehm, Michael, Papaioannou, Georgios, Becker, David, Battler, Alexander, Lewis, Basil, Behar, Shlomo, Erglis, Andrejs, Navickas, Ramunas, Koch, Karel T., ter Burg, Willem J., Polonski, Lech, Deleanu, Dan, Tatu-Chitoiu, Gabriel, Baráková, Anna, Hlava, Peter, Murín, Ján, Kamenský, Gabriel, Kaliská, Gabriela, Albarrang, Agustin, Hernandez, Felipe, Windecker, Stephan, Eeckhout, Eric, Kozan, Omer, Enar, Rasim, and Birkhead, John

Published
2010
Full Text
View/download PDF

26. Rationale and design of the EU-CERT-ICD prospective study: comparative effectiveness of prophylactic ICD implantation

Author

Zabel, Markus, Sticherling, Christian, Willems, Rik, Lubinski, Andrzej, Bauer, Axel, Bergau, Leonard, Braunschweig, Frieder, Brugada, Josep, Brusich, Sandro, Conen, David, Cygankiewicz, Iwona, Flevari, Panagiota, Taborsky, Milos, Hansen, Jim, Hasenfuss, Gerd, Hatala, Robert, Huikuri, Heikki V, Iovev, Svetoslav, Kaeaeb, Stefan, Kaliska, Gabriela, Kasprzak, Jaroslaw D, Luethje, Lars, Malik, Marek, Novotny, Tomas, Pavlovic, Nikola, Schmidt, Georg, Shalganov, Tchavdar, Sritharan, Rajeeva, Schloegl, Simon, Traykov, Vassil, Tuinenburg, Anton E, Velchev, Vasil, Vos, Marc A, Willich, Stefan N, Friede, Tim, Svendsen, Jesper Hastrup, Merkely, Bela, Seegers, J, Munoz-Exposito, P, Tichelbacker, T, Kirovo, A, Joerss, K, Macken, J, Misdaq, M, Rudolph, K, Mueller, A, Dommasch, M, Sinnecker, D, Sinner, M, Dissmann, R, Burmester, U, Behrens, S, Gregor, M, Stefanow, S, Rueb, N, Wolpert, C, Bimmel, D, Lieberz, C, Maier, L, Schwinger, R, Blaschke, F, Pieske, B, Groenefeld, G, Klein, G, Gardiwal, A, Szeplaki, G, Perge, P, Nossan, J Szavits, Rotkvic, L, Manola, S, Vinter, O, Benko, I, Brusic, S, Avdovic, E, Klasan, M, Bakotic, Z, Anic, A, Kowalczyk, E, Kucejko, T, Czechowska, A, Wybor, K, Ptaszynski, P, Qavoq, H, Guzik, P, Krauze, T, Sterlinski, M, Svetlosak, M, Martinek, J, Thamsborg, K, Schloett-Hyldelund, IM, Laage-Petersen, J, Vandenberk, B, van Soest, S, Giesebart, S, Kozak, M, Galuszka, J, Wijers, S, Dunnink, A, Sprenkeler, D, Arbelo, E, Trucco, E, Vidorreta, S, Kentta, T, Pelli, A, Huikuri, P, Koski, P, Karlsson, H, Ersgaard, D, Platonov, P, Klingenheben, T, Scharfe, M, Reinhold, T, Cree, M, Hnatkova, K, Gerhardt, J, Rizas, K, Hamm, W, Roever, C, Harden, M, Kessel, B, Berg, A, Apel, S, Walker, F, Kirchhof, N, Goerlitz, A, Molitor, A, Heinrich, J, Annetzberger, S, Fuchs, B, Landwehr, A, Merk, A, Wilke, A, Hennecke, C, and Mansch, R

Subjects
Science & Technology, Cardiac & Cardiovascular Systems, SEX-DIFFERENCES, SEATTLE HEART-FAILURE, RISK STRATIFICATION, EJECTION FRACTION, Sudden cardiac death, Risk factors, MYOCARDIAL-INFARCTION, CARDIOVERTER-DEFIBRILLATOR THERAPY, Implantable cardioverter defibrillator, Cardiovascular System & Cardiology, APPROPRIATE SHOCKS, Mortality, PRIMARY PREVENTION, PROPORTIONAL RISK, Life Sciences & Biomedicine
Abstract

AIMS: The clinical effectiveness of primary prevention implantable cardioverter defibrillator (ICD) therapy is under debate. The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators (EU-CERT-ICD) aims to assess its current clinical value. METHODS AND RESULTS: The EU-CERT-ICD is a prospective investigator-initiated non-randomized, controlled, multicentre observational cohort study performed in 44 centres across 15 European Union countries. We will recruit 2250 patients with ischaemic or dilated cardiomyopathy and a guideline indication for primary prophylactic ICD implantation. This sample will include 1500 patients at their first ICD implantation and 750 patients who did not receive a primary prevention ICD despite having an indication for it (non-randomized control group). The primary endpoint is all-cause mortality; the co-primary endpoint in ICD patients is time to first appropriate shock. Secondary endpoints include sudden cardiac death, first inappropriate shock, any ICD shock, arrhythmogenic syncope, revision procedures, quality of life, and cost-effectiveness. At baseline (and prior to ICD implantation if applicable), all patients undergo 12-lead electrocardiogram (ECG) and Holter ECG analysis using multiple advanced methods for risk stratification as well as detailed documentation of clinical characteristics and laboratory values. Genetic biobanking is also organized. As of August 2018, baseline data of 2265 patients are complete. All subjects will be followed for up to 4.5 years. CONCLUSIONS: The EU-CERT-ICD study will provide a necessary update about clinical effectiveness of primary prophylactic ICD implantation. This study also aims for improved risk stratification and patient selection using clinical and ECG risk markers. ispartof: ESC HEART FAILURE vol:6 issue:1 pages:182-193 ispartof: location:England status: published

Published
2019

27. Atrial high-rate episodes : prevalence, stroke risk, implications for management, and clinical gaps in evidence

Author

Bertaglia, Emanuele, Blank, Benjamin, Blomström-Lundqvist, Carina, Brandes, Axel, Cabanelas, Nuno, Dan, G-Andrei, Dichtl, Wolfgang, Goette, Andreas, de Groot, Joris R, Lubinski, Andrzej, Marijon, Eloi, Merkely, Béla, Mont, Lluis, Piorkowski, Christopher, Sarkozy, Andrea, Sulke, Neil, Vardas, Panos, Velchev, Vasil, Wichterle, Dan, Kirchhof, Paulus, Bertaglia, Emanuele, Blank, Benjamin, Blomström-Lundqvist, Carina, Brandes, Axel, Cabanelas, Nuno, Dan, G-Andrei, Dichtl, Wolfgang, Goette, Andreas, de Groot, Joris R, Lubinski, Andrzej, Marijon, Eloi, Merkely, Béla, Mont, Lluis, Piorkowski, Christopher, Sarkozy, Andrea, Sulke, Neil, Vardas, Panos, Velchev, Vasil, Wichterle, Dan, and Kirchhof, Paulus

Abstract

Self-terminating atrial arrhythmias are commonly detected on continuous rhythm monitoring, e.g. by pacemakers or defibrillators. It is unclear whether the presence of these arrhythmias has therapeutic consequences. We sought to summarize evidence on the prevalence of atrial high-rate episodes (AHREs) and their impact on risk of stroke. We performed a comprehensive, tabulated review of published literature on the prevalence of AHRE. In patients with AHRE, but without atrial fibrillation (AF), we reviewed the stroke risk and the potential risk/benefit of oral anticoagulation. Atrial high-rate episodes are found in 10-30% of AF-free patients. Presence of AHRE slightly increases stroke risk (0.8% to 1%/year) compared with patients without AHRE. Atrial high-rate episode of longer duration (e.g. those >24 h) could be associated with a higher stroke risk. Oral anticoagulation has the potential to reduce stroke risk in patients with AHRE but is associated with a rate of major bleeding of 2%/year. Oral anticoagulation is not effective in patients with heart failure or survivors of a stroke without AF. It remains unclear whether anticoagulation is effective and safe in patients with AHRE. Atrial high-rate episodes are common and confer a slight increase in stroke risk. There is true equipoise on the best way to reduce stroke risk in patients with AHRE. Two ongoing trials (NOAH-AFNET 6 and ARTESiA) will provide much-needed information on the effectiveness and safety of oral anticoagulation using non-vitamin K antagonist oral anticoagulants in patients with AHRE.

Published
2019
Full Text
View/download PDF

28. Rationale and design of the EU-CERT-ICD prospective study:comparative effectiveness of prophylactic ICD implantation

Author

Zabel, Markus, Sticherling, Christian, Willems, Rik, Lubinski, Andrzej, Bauer, Axel, Bergau, Leonard, Braunschweig, Frieder, Brugada, Josep, Brusich, Sandro, Conen, David, Cygankiewicz, Iwona, Flevari, Panagiota, Taborsky, Milos, Hansen, Jim, Hasenfuß, Gerd, Hatala, Robert, Huikuri, Heikki V., Iovev, Svetoslav, Kääb, Stefan, Kaliska, Gabriela, Kasprzak, Jaroslaw D., Lüthje, Lars, Malik, Marek, Novotny, Tomas, Pavlović, Nikola, Schmidt, Georg, Shalganov, Tchavdar, Sritharan, Rajeeva, Schlögl, Simon, Szavits Nossan, Janko, Traykov, Vassil, Tuinenburg, Anton E., Velchev, Vasil, Vos, Marc A., Willich, Stefan N., Friede, Tim, Svendsen, Jesper Hastrup, Merkely, Béla, Zabel, Markus, Sticherling, Christian, Willems, Rik, Lubinski, Andrzej, Bauer, Axel, Bergau, Leonard, Braunschweig, Frieder, Brugada, Josep, Brusich, Sandro, Conen, David, Cygankiewicz, Iwona, Flevari, Panagiota, Taborsky, Milos, Hansen, Jim, Hasenfuß, Gerd, Hatala, Robert, Huikuri, Heikki V., Iovev, Svetoslav, Kääb, Stefan, Kaliska, Gabriela, Kasprzak, Jaroslaw D., Lüthje, Lars, Malik, Marek, Novotny, Tomas, Pavlović, Nikola, Schmidt, Georg, Shalganov, Tchavdar, Sritharan, Rajeeva, Schlögl, Simon, Szavits Nossan, Janko, Traykov, Vassil, Tuinenburg, Anton E., Velchev, Vasil, Vos, Marc A., Willich, Stefan N., Friede, Tim, Svendsen, Jesper Hastrup, and Merkely, Béla

Abstract

Aims: The clinical effectiveness of primary prevention implantable cardioverter defibrillator (ICD) therapy is under debate. The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators (EU-CERT-ICD) aims to assess its current clinical value. Methods and results: The EU-CERT-ICD is a prospective investigator-initiated non-randomized, controlled, multicentre observational cohort study performed in 44 centres across 15 European Union countries. We will recruit 2250 patients with ischaemic or dilated cardiomyopathy and a guideline indication for primary prophylactic ICD implantation. This sample will include 1500 patients at their first ICD implantation and 750 patients who did not receive a primary prevention ICD despite having an indication for it (non-randomized control group). The primary endpoint is all-cause mortality; the co-primary endpoint in ICD patients is time to first appropriate shock. Secondary endpoints include sudden cardiac death, first inappropriate shock, any ICD shock, arrhythmogenic syncope, revision procedures, quality of life, and cost-effectiveness. At baseline (and prior to ICD implantation if applicable), all patients undergo 12-lead electrocardiogram (ECG) and Holter ECG analysis using multiple advanced methods for risk stratification as well as detailed documentation of clinical characteristics and laboratory values. Genetic biobanking is also organized. As of August 2018, baseline data of 2265 patients are complete. All subjects will be followed for up to 4.5 years. Conclusions: The EU-CERT-ICD study will provide a necessary update about clinical effectiveness of primary prophylactic ICD implantation. This study also aims for improved risk stratification and patient selection using clinical and ECG risk markers.

Published
2019

29. European Society of Cardiology: Cardiovascular Disease Statistics 2017

Author

Timmis, Adam, Townsend, Nick, Gale, Chris, Grobbee, Rick, Maniadakis, Nikos, Flather, Marcus, Wilkins, Elizabeth, Wright, Lucy, Vos, Rimke, Bax, Jeroen, Blum, Maxim, Logstrup, Susanne, Pinto, Fausto J., Vardas, Panos, Goda, Artan, Demiraj, Aurel F, Weidinger, Franz, Metzler, Bernard, Ibrahimov, Firdovsi, Pasquet, Agnes A, Claeys, Marc, Thorton, Yolanda, Kusljugic, Zumreta, Smajic, Elnur, Velchev, Vasil, Ivanov, Nikolay, Antoniades, Loizos, Agathangelou, Petros, Táborský, Miloš, Gerdes, Christian, Viigima, Margus, Juhani, Pietila Mikko, Juilliere, Yves, Cattan, Simon, Aladashvili, Alexander, Hamm, Christian, Kuck, Karl-Heinz, Papoutsis, Konstantinos, Bestehorn, Kurt, Foussas, Stefanos, Giannoulidou, Georgia, Varounis, Christos, Kallikazaros, Ioannis, Kiss, Robert Gabor, Czétényi, Tunde, Becker, Dávid, Gudnason, Thorarinn, Kearney, Peter, McDonald, Kenneth, Rozenman, Yoseph, Ziv, Batia, Bolognese, Leonardo, Luciolli, Paola, Boriani, Giuseppe, Berkinbayev, Salim, Rakisheva, Amina, Mirrakhimov, Erkin, Erglis, Andrejs, Jegere, Sandra, Marinskis, Germanas, Beissel, Jean, Marchal, Nathalie, Kedev, Sasko, Xuereb, Robert G, Tilney, Terence, Felice, Tiziana, Popovici, Mihail, Mulder, Barbara, Simoons, Maarten, Elsendoorn, Moniek, Steigen, Terje K, Atar, Dan, Kalarus, Zbigniew, Tendera, Michal, Cardoso, Jose Silva, Ribeiro, José, Mateus, Cristina, Tatu-Chitoiu, Gabriel, Seferovic, Petar, Beleslin, Branko, Simkova, Iveta, Durcikova, Petra, Belicova, Veronica, Fras, Zlatko, Radelj, Sasa, Gonzalez Juanatey, Jose Ramon, Legendre, Sharon, Braunschweig, Frieder, Kaufmann, Urs Philipp, Rudiger-Sturchler, Marjam, Tokgozoglu, Lale, Unver, Ahmet, Kovalenko, Volodymir, Nesukay, Elena, Naum, Anastasia, de Courtelary, Paola Thellung, Martin, Stephan, Sebastiao, David, Ghislain, Daval, Bardinet, Isabel, and Repositório da Universidade de Lisboa

Subjects
medicine.medical_specialty, Inequality, media_common.quotation_subject, Health infrastructure, Disease, 030204 cardiovascular system & hematology, European Society of Cardiology, 03 medical and health sciences, 0302 clinical medicine, Economic indicator, Internal medicine, Health care, Statistics, medicine, Cardiovascular disease, Morbidity, Mortality, Risk factors, Service provision, Cardiology and Cardiovascular Medicine, 030212 general & internal medicine, Disease burden, Cause of death, media_common, business.industry, medicine.disease, Obesity, Years of potential life lost, Cardiology, business
Abstract

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: journals.permissions@oup.com., Aims: The European Society of Cardiology (ESC) Atlas has been compiled by the European Heart Agency to document cardiovascular disease (CVD) statistics of the 56 ESC member countries. A major aim of this 2017 data presentation has been to compare high-income and middle-income ESC member countries to identify inequalities in disease burden, outcomes, and service provision. Methods and results: The Atlas utilizes a variety of data sources, including the World Health Organization, the Institute for Health Metrics and Evaluation, and the World Bank to document risk factors, prevalence, and mortality of cardiovascular disease and national economic indicators. It also includes novel ESC-sponsored survey data of health infrastructure and cardiovascular service provision provided by the national societies of the ESC member countries. Data presentation is descriptive with no attempt to attach statistical significance to differences observed in stratified analyses. Important differences were identified between the high-income and middle-income member countries of the ESC with regard to CVD risk factors, disease incidence, and mortality. For both women and men, the age-standardized prevalence of hypertension was lower in high-income countries (18% and 27%) compared with middle-income countries (24% and 30%). Smoking prevalence in men (not women) was also lower (26% vs. 41%) and together these inequalities are likely to have contributed to the higher CVD mortality in middle-income countries. Declines in CVD mortality have seen cancer becoming a more common cause of death in a number of high-income member countries, but in middle-income countries declines in CVD mortality have been less consistent where CVD remains the leading cause of death. Inequalities in CVD mortality are emphasized by the smaller contribution they make to potential years of life lost in high-income countries compared with middle-income countries both for women (13% vs. 23%) and men (20% vs. 27%). The downward mortality trends for CVD may, however, be threatened by the emerging obesity epidemic that is seeing rates of diabetes increasing across all the ESC member countries. Survey data from the National Cardiac Societies showed that rates of cardiac catheterization and coronary artery bypass surgery, as well as the number of specialist centres required to deliver them, were greatest in the high-income member countries of the ESC. The Atlas confirmed that these ESC member countries, where the facilities for the contemporary treatment of coronary disease were best developed, were often those in which declines in coronary mortality have been most pronounced. Economic resources were not the only driver for delivery of equitable cardiovascular health care, as some middle-income ESC member countries reported rates for interventional procedures and device implantations that matched or exceeded the rates in wealthier member countries. Conclusion: In documenting national CVD statistics, the Atlas provides valuable insights into the inequalities in risk factors, health care delivery, and outcomes of CVD across the ESC member countries. The availability of these data will underpin the ESC’s ambitious mission ‘to reduce the burden of cardiovascular disease’ not only in its member countries but also in nation states around the world.

Published
2018

30. Present criteria for prophylactic ICD implantation: Insights from the EU-CERT-ICD (Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in EUrope) project

Author

Zabel, Markus, primary, Schlögl, Simon, additional, Lubinski, Andrzej, additional, Svendsen, Jesper Hastrup, additional, Bauer, Axel, additional, Arbelo, Elena, additional, Brusich, Sandro, additional, Conen, David, additional, Cygankiewicz, Iwona, additional, Dommasch, Michael, additional, Flevari, Panagiota, additional, Galuszka, Jan, additional, Hansen, Jim, additional, Hasenfuß, Gerd, additional, Hatala, Robert, additional, Huikuri, Heikki V., additional, Kenttä, Tuomas, additional, Kucejko, Tomasz, additional, Haarmann, Helge, additional, Harden, Markus, additional, Iovev, Svetoslav, additional, Kääb, Stefan, additional, Kaliska, Gabriela, additional, Katsimardos, Andreas, additional, Kasprzak, Jaroslaw D., additional, Qavoq, Dariusz, additional, Lüthje, Lars, additional, Malik, Marek, additional, Novotný, Tomáš, additional, Pavlović, Nikola, additional, Perge, Peter, additional, Röver, Christian, additional, Schmidt, Georg, additional, Shalganov, Tchavdar, additional, Sritharan, Rajeeva, additional, Svetlosak, Martin, additional, Sallo, Zoltan, additional, Szavits-Nossan, Janko, additional, Traykov, Vassil, additional, Vandenberk, Bert, additional, Velchev, Vasil, additional, Vos, Marc A., additional, Willich, Stefan N., additional, Friede, Tim, additional, Willems, Rik, additional, Merkely, Béla, additional, and Sticherling, Christian, additional

Published
2019
Full Text
View/download PDF

31. Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study

Author

Bauer, Axel, primary, Klemm, Mathias, additional, Rizas, Konstantinos D, additional, Hamm, Wolfgang, additional, von Stülpnagel, Lukas, additional, Dommasch, Michael, additional, Steger, Alexander, additional, Lubinski, Andrezej, additional, Flevari, Panagiota, additional, Harden, Markus, additional, Friede, Tim, additional, Kääb, Stefan, additional, Merkely, Bela, additional, Sticherling, Christian, additional, Willems, Rik, additional, Huikuri, Heikki, additional, Malik, Marek, additional, Schmidt, Georg, additional, Zabel, Markus, additional, Merkely, Béla, additional, Perge, Peter, additional, Sallo, Zoltan, additional, Szeplaki, Gabor, additional, Lüthje, Lars, additional, Schlögl, Simon, additional, Haarmann, Helge, additional, Bergau, Leonard, additional, Seegers, Joachim, additional, Hasenfuß, Gerd, additional, Munoz-Exposito, Pascal, additional, Tichelbäcker, Tobias, additional, Kirova, Aleksandra, additional, Hnatkova, Katerina, additional, Vos, Marc, additional, Willich, Stefan N., additional, Reinhold, Thomas, additional, Vandenberk, Bert, additional, Klinika, Magdalena, additional, Toplice, Krapinske, additional, Flevari, Panayota, additional, Katsimardos, Andreas, additional, Katsaras, Dimitrios, additional, Hatala, Robert, additional, Svetlosak, Martin, additional, Lubinski, Andrzej, additional, Kuczejko, Tomasz, additional, Hansen, Jim, additional, Conen, David, additional, Milosrdnice, Sestre, additional, Pavlović, Nikola, additional, Manola, Šime, additional, Vinter, Ozren, additional, Benko, Ivica, additional, Tuinenburg, Anton, additional, Bauer, Axel, additional, Meyer-Zürn, Christine, additional, Eick, Christian, additional, Hastrup, Jesper, additional, Brugada, Josep, additional, Arbelo, Elena, additional, Kaliska, Gabriela, additional, Martinek, Jozef, additional, Sinner, Moritz F., additional, Rizas, Konstantinos D., additional, Vdovin, Nikolay, additional, Cygankiewicz, Iwona, additional, Ptaszynski, Pawel, additional, Kaczmarek, Krzysztof, additional, Poddebska, Izabela, additional, Iovev, Svetoslav, additional, Novotný, Tomáš, additional, Kozak, Milan, additional, Kenttä, Tuomas, additional, Pelli, Ari, additional, Kasprzak, Jaroslaw D., additional, Qavoq, Dariusz, additional, Brusich, Sandro, additional, Avdovic, Ervin, additional, Klasan, Marina, additional, Galuszka, Jan, additional, Taborsky, Milos, additional, Velchev, Vasil, additional, Dissmann, Rüdiger, additional, Guzik, Przemysław, additional, Bimmel, Dieter, additional, Lieberz, Christiane, additional, Stefanow, Stefan, additional, Rüb, Norman, additional, Wolpert, Christian, additional, Maier, Lars S., additional, Behrens, Steffen, additional, Jurisic, Zrinka, additional, Braunschweig, Frieder, additional, Blaschke, Florian, additional, Pieske, Burkert, additional, Bakotic, Zoran, additional, Anic, Ante, additional, Schwinger, Robert H.G., additional, and Platonov, Pyotr, additional

Published
2019
Full Text
View/download PDF

32. Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence

Author

Bertaglia, Emanuele, primary, Blank, Benjamin, additional, Blomström-Lundqvist, Carina, additional, Brandes, Axel, additional, Cabanelas, Nuno, additional, Dan, G -Andrei, additional, Dichtl, Wolfgang, additional, Goette, Andreas, additional, de Groot, Joris R, additional, Lubinski, Andrzej, additional, Marijon, Eloi, additional, Merkely, Béla, additional, Mont, Lluis, additional, Piorkowski, Christopher, additional, Sarkozy, Andrea, additional, Sulke, Neil, additional, Vardas, Panos, additional, Velchev, Vasil, additional, Wichterle, Dan, additional, and Kirchhof, Paulus, additional

Published
2019
Full Text
View/download PDF

33. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

Author

Vranckx, Pascal, primary, Valgimigli, Marco, additional, Jüni, Peter, additional, Hamm, Christian, additional, Steg, Philippe Gabriel, additional, Heg, Dik, additional, van Es, Gerrit Anne, additional, McFadden, Eugene P, additional, Onuma, Yoshinobu, additional, van Meijeren, Cokky, additional, Chichareon, Ply, additional, Benit, Edouard, additional, Möllmann, Helge, additional, Janssens, Luc, additional, Ferrario, Maurizio, additional, Moschovitis, Aris, additional, Zurakowski, Aleksander, additional, Dominici, Marcello, additional, Van Geuns, Robert Jan, additional, Huber, Kurt, additional, Slagboom, Ton, additional, Serruys, Patrick W, additional, Windecker, Stephan, additional, Abdellaoui, Mohamed, additional, Adlam, David, additional, Akin, Ibrahim, additional, Albarran Gonzalez-Trevilla, Agustin, additional, Almeida, Manuel, additional, Alves Lemos Neto, Pedro, additional, Aminian, Adel, additional, Anderson, Richard, additional, Andreae, Rick, additional, Angioi, Michael, additional, Asano, Taku, additional, Barbato, Emanuele, additional, Barlis, Peter, additional, Barraud, Pascal, additional, Bertrand, Olivier, additional, Beygui, Farzin, additional, Bolognese, Leonardo, additional, Botelho, Roberto, additional, Bouwman, Coby, additional, Bressers, Marco, additional, Brunel, Philippe, additional, Buszman, Pawel, additional, Buysschaert, Ian, additional, Canas da Silva, Pedro, additional, Carrie, Didier, additional, Cequier, Angel, additional, Chin Chang, Chun, additional, Chowdhary, Saqib, additional, Collet, Carlos, additional, Colombo, Antonio, additional, Cotton, James, additional, Cruz Ferreira, Rui, additional, Curello, Salvatore, additional, Curzen, Nick, additional, de Bot, Judith, additional, de Vreede, Tone, additional, Delle Karth, Georg, additional, Dijksma, Lynn, additional, Édes, István, additional, Eeckhout, Eric, additional, Eitel, Ingo, additional, Faluközy, József, additional, Fath-Ordoubadi, Farzin, additional, Fontos, Geza, additional, Francisco Diaz, Jose, additional, Freitas Quintella, Edgard, additional, Frey, Bernhard, additional, Friedrich, Guy, additional, Galasko, Gavin, additional, Galuszka, Grzegorz, additional, Gama Ribeiro, Vasco, additional, Garg, Scot, additional, Gargiulo, Giuseppe, additional, Geisler, Tobias, additional, Gelev, Valeri, additional, Ghandilyan, Art, additional, Goicolea, Javier, additional, Gori, Tommaso, additional, Gragnano, Felice, additional, Guimarães, Ana, additional, Haude, Michael, additional, Heijke, Pieter, additional, Hernández Antolin, Rosa Ana, additional, Hildick-Smith, David, additional, Hillen, Dorien, additional, Hoekman, Ina, additional, Hofma, Sjoerd, additional, Holmvang, Lene, additional, Hoole, Stephen, additional, Horváth, Iván, additional, Hugense, Annemarie, additional, Ibrahim, Karim, additional, Iñiguez, Andres, additional, Isaaz, Karl, additional, Jambrik, Zoltán, additional, Jasionowicz, Pawel, additional, Jonk, Judith, additional, Jung, Werner, additional, Katagiri, Yuki, additional, Kogame, Norihiro, additional, Koh, Tian Hai, additional, Koning, René, additional, Konteva, Mariana, additional, Kőszegi, Zsolt, additional, Krackhardt, Florian, additional, Kreuger, Yvonne, additional, Kukreja, Neville, additional, Ladan, Boudijn, additional, Lantelme, Pierre, additional, Leandro, Sergio, additional, Leibundgut, Gregor, additional, Liebetrau, Christoph, additional, Lindeboom, Wietze, additional, Macaya Miguel, Carlos, additional, Mach, François, additional, Magro, Michael, additional, Maillard, Luc, additional, Manavifar, Negar, additional, Mauri, Laura, additional, McFadden, Eugene, additional, Merkely, Bela, additional, Miyazaki, Yosuke, additional, Młodziankowski, Adam, additional, Moccetti, Tiziano, additional, Modolo, Rodrigo, additional, Möllman, Helge, additional, Morelle, Jean-François, additional, Munndt Ottesen, Michael, additional, Muurling, Martin, additional, Naber, Christoph Kurt, additional, Neumann, Franz-Josef, additional, Oldroyd, Keith, additional, Ong, Paul, additional, Palsrok, Sanne, additional, Petrov, Ivo, additional, Plante, Sylvain, additional, Prokopczuk, Janusz, additional, Rademaker-Havinga, Tessa, additional, Raffel, Christopher, additional, Rensing, Benno, additional, Roffi, Marco, additional, Royaards, Kees-Jan, additional, Sabate, Manel, additional, Schächinger, Volker, additional, Seidler, Tim, additional, Serra Peñaranda, Antonio, additional, Serruys, Patrick, additional, Sikarulidze, Lali, additional, Soliman, Osama I, additional, Sousa, Amanda, additional, Spitzer, Ernest, additional, Stables, Rod, additional, Steg, Gabriel, additional, Steinwender, Clemens, additional, Subkovas, Eduardas, additional, Suryapranata, Harry, additional, Takahashi, Kuniaki, additional, Talwar, Suneel, additional, Teiger, Emmanuel, additional, ter Weele, Addy, additional, Teurlings, Eva, additional, Thury, Attila, additional, Tijssen, Jan, additional, Tonev, Gincho, additional, Trendafilova-Lazarova, Diana, additional, Tumscitz, Carlo, additional, Umans, Victor, additional, Ungi, Imre, additional, Valkov, Veselin, additional, van der Harst, Pim, additional, van Geuns, Robert Jan, additional, Vassilev, Dobrin, additional, Velchev, Vasil, additional, Velthuizen, Esther, additional, Verheugt, Freek, additional, Vlcek, Natalia, additional, vom Dahl, Jürgen, additional, Vrolix, Mathias, additional, Walsh, Simon, additional, Werner, Nikos, additional, Witsenburg, Maarten, additional, Zaman, Azfar, additional, Żmudka, Krzysztof, additional, Zrenner, Bernhard, additional, and Zweiker, Robert, additional

Published
2018
Full Text
View/download PDF

35. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vsaspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

Author

Vranckx, Pascal, Valgimigli, Marco, Jüni, Peter, Hamm, Christian, Steg, Philippe Gabriel, Heg, Dik, van Es, Gerrit Anne, McFadden, Eugene P, Onuma, Yoshinobu, van Meijeren, Cokky, Chichareon, Ply, Benit, Edouard, Möllmann, Helge, Janssens, Luc, Ferrario, Maurizio, Moschovitis, Aris, Zurakowski, Aleksander, Dominici, Marcello, Van Geuns, Robert Jan, Huber, Kurt, Slagboom, Ton, Serruys, Patrick W, Windecker, Stephan, Abdellaoui, Mohamed, Adlam, David, Akin, Ibrahim, Albarran Gonzalez-Trevilla, Agustin, Almeida, Manuel, Alves Lemos Neto, Pedro, Aminian, Adel, Anderson, Richard, Andreae, Rick, Angioi, Michael, Asano, Taku, Barbato, Emanuele, Barlis, Peter, Barraud, Pascal, Benit, Edouard, Bertrand, Olivier, Beygui, Farzin, Bolognese, Leonardo, Botelho, Roberto, Bouwman, Coby, Bressers, Marco, Brunel, Philippe, Buszman, Pawel, Buysschaert, Ian, Canas da Silva, Pedro, Carrie, Didier, Cequier, Angel, Chichareon, Ply, Chin Chang, Chun, Chowdhary, Saqib, Collet, Carlos, Colombo, Antonio, Cotton, James, Cruz Ferreira, Rui, Curello, Salvatore, Curzen, Nick, de Bot, Judith, de Vreede, Tone, Delle Karth, Georg, Dijksma, Lynn, Dominici, Marcello, Édes, István, Eeckhout, Eric, Eitel, Ingo, Faluközy, József, Fath-Ordoubadi, Farzin, Ferrario, Maurizio, Fontos, Geza, Francisco Diaz, Jose, Freitas Quintella, Edgard, Frey, Bernhard, Friedrich, Guy, Galasko, Gavin, Galuszka, Grzegorz, Gama Ribeiro, Vasco, Garg, Scot, Gargiulo, Giuseppe, Geisler, Tobias, Gelev, Valeri, Ghandilyan, Art, Goicolea, Javier, Gori, Tommaso, Gragnano, Felice, Guimarães, Ana, Hamm, Christian, Haude, Michael, Heg, Dik, Heijke, Pieter, Hernández Antolin, Rosa Ana, Hildick-Smith, David, Hillen, Dorien, Hoekman, Ina, Hofma, Sjoerd, Holmvang, Lene, Hoole, Stephen, Horváth, Iván, Huber, Kurt, Hugense, Annemarie, Ibrahim, Karim, Iñiguez, Andres, Isaaz, Karl, Jambrik, Zoltán, Janssens, Luc, Jasionowicz, Pawel, Jonk, Judith, Jung, Werner, Jüni, Peter, Katagiri, Yuki, Kogame, Norihiro, Koh, Tian Hai, Koning, René, Konteva, Mariana, Kőszegi, Zsolt, Krackhardt, Florian, Kreuger, Yvonne, Kukreja, Neville, Ladan, Boudijn, Lantelme, Pierre, Leandro, Sergio, Leibundgut, Gregor, Liebetrau, Christoph, Lindeboom, Wietze, Macaya Miguel, Carlos, Mach, François, Magro, Michael, Maillard, Luc, Manavifar, Negar, Mauri, Laura, McFadden, Eugene, Merkely, Bela, Miyazaki, Yosuke, Młodziankowski, Adam, Moccetti, Tiziano, Modolo, Rodrigo, Möllman, Helge, Morelle, Jean-François, Moschovitis, Aris, Munndt Ottesen, Michael, Muurling, Martin, Naber, Christoph Kurt, Neumann, Franz-Josef, Oldroyd, Keith, Ong, Paul, Onuma, Yoshinobu, Palsrok, Sanne, Petrov, Ivo, Plante, Sylvain, Prokopczuk, Janusz, Rademaker-Havinga, Tessa, Raffel, Christopher, Rensing, Benno, Roffi, Marco, Royaards, Kees-Jan, Sabate, Manel, Schächinger, Volker, Seidler, Tim, Serra Peñaranda, Antonio, Serruys, Patrick, Sikarulidze, Lali, Slagboom, Ton, Soliman, Osama I, Sousa, Amanda, Spitzer, Ernest, Stables, Rod, Steg, Gabriel, Steinwender, Clemens, Subkovas, Eduardas, Suryapranata, Harry, Takahashi, Kuniaki, Talwar, Suneel, Teiger, Emmanuel, ter Weele, Addy, Teurlings, Eva, Thury, Attila, Tijssen, Jan, Tonev, Gincho, Trendafilova-Lazarova, Diana, Tumscitz, Carlo, Umans, Victor, Ungi, Imre, Valkov, Veselin, van der Harst, Pim, van Geuns, Robert Jan, van Meijeren, Cokky, Vassilev, Dobrin, Velchev, Vasil, Velthuizen, Esther, Verheugt, Freek, Vlcek, Natalia, vom Dahl, Jürgen, Vrolix, Mathias, Walsh, Simon, Werner, Nikos, Windecker, Stephan, Witsenburg, Maarten, Zaman, Azfar, Żmudka, Krzysztof, Zrenner, Bernhard, Zurakowski, Aleksander, and Zweiker, Robert

Abstract

We hypothesised that ticagrelor, in combination with aspirin for 1 month, followed by ticagrelor alone, improves outcomes after percutaneous coronary intervention compared with standard antiplatelet regimens.

Published
2018
Full Text
View/download PDF

38. Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥24 h.

Author

Becher N, Toennis T, Bertaglia E, Blomström-Lundqvist C, Brandes A, Cabanelas N, Calvert M, Camm AJ, Chlouverakis G, Dan GA, Dichtl W, Diener HC, Fierenz A, Goette A, de Groot JR, Hermans ANL, Lip GYH, Lubinski A, Marijon E, Merkely B, Mont L, Ozga AK, Rajappan K, Sarkozy A, Scherr D, Schnabel RB, Schotten U, Sehner S, Simantirakis E, Vardas P, Velchev V, Wichterle D, Zapf A, and Kirchhof P

Subjects
Humans, Female, Aged, Aged, 80 and over, Male, Heart Atria, Risk Factors, Anticoagulants therapeutic use, Atrial Fibrillation complications, Atrial Fibrillation drug therapy, Atrial Fibrillation diagnosis, Stroke etiology, Stroke prevention & control, Stroke diagnosis, Pyridines, Thiazoles
Abstract

Background and Aims: Patients with long atrial high-rate episodes (AHREs) ≥24 h and stroke risk factors are often treated with anticoagulation for stroke prevention. Anticoagulation has never been compared with no anticoagulation in these patients., Methods: This secondary pre-specified analysis of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High-rate episodes (NOAH-AFNET 6) trial examined interactions between AHRE duration at baseline and anticoagulation with edoxaban compared with placebo in patients with AHRE and stroke risk factors. The primary efficacy outcome was a composite of stroke, systemic embolism, or cardiovascular death. The safety outcome was a composite of major bleeding and death. Key secondary outcomes were components of these outcomes and electrocardiogram (ECG)-diagnosed atrial fibrillation., Results: Median follow-up of 2389 patients with core lab-verified AHRE was 1.8 years. AHRE ≥24 h were present at baseline in 259/2389 patients (11%, 78 ± 7 years old, 28% women, CHA2DS2-VASc 4). Clinical characteristics were not different from patients with shorter AHRE. The primary outcome occurred in 9/132 patients with AHRE ≥24 h (4.3%/patient-year, 2 strokes) treated with anticoagulation and in 14/127 patients treated with placebo (6.9%/patient-year, 2 strokes). Atrial high-rate episode duration did not interact with the efficacy (P-interaction = .65) or safety (P-interaction = .98) of anticoagulation. Analyses including AHRE as a continuous parameter confirmed this. Patients with AHRE ≥24 h developed more ECG-diagnosed atrial fibrillation (17.0%/patient-year) than patients with shorter AHRE (8.2%/patient-year; P < .001)., Conclusions: This hypothesis-generating analysis does not find an interaction between AHRE duration and anticoagulation therapy in patients with device-detected AHRE and stroke risk factors. Further research is needed to identify patients with long AHRE at high stroke risk., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Published
2024
Full Text
View/download PDF

39. Endovascular iliac vein recanalization for permanent pacemaker implantation in a patient who has long-term haemodialysis: a case report.

Author

Stoyanov N, Goranovska V, Gegouskov V, and Velchev V

Abstract

Background: In chronic haemodialysis patients central veins occlusion occur very often. In such patients, permanent pacemaker placement implantation can be challenging and alternative approaches should be used., Case Summary: This is a case of 66-year-old male patient with complete atrioventricular block after a mitral valve (MV) surgery for endocarditis. The patient has a permanent surgically inserted haemodialysis catheter in right heart atrium after several unsuccessful attempts of endovascular recanalization of superior vena cava. A lead was implanted in the right ventricle after successful endovascular revascularization of the right iliac vein. The pacemaker was placed in a pouch on the right lower abdominal wall., Discussion: To our knowledge, this is the first reported case where a permanent single-chamber pacemaker was implanted through the right iliac vein after successful endovascular recanalization in chronic haemodialysis patient post-MV replacement., (© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Published
2020
Full Text
View/download PDF

40. Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence.

Author

Bertaglia E, Blank B, Blomström-Lundqvist C, Brandes A, Cabanelas N, Dan GA, Dichtl W, Goette A, de Groot JR, Lubinski A, Marijon E, Merkely B, Mont L, Piorkowski C, Sarkozy A, Sulke N, Vardas P, Velchev V, Wichterle D, and Kirchhof P

Subjects
Atrial Fibrillation complications, Atrial Fibrillation drug therapy, Global Health, Humans, Prevalence, Risk Factors, Stroke etiology, Stroke prevention & control, Anticoagulants therapeutic use, Atrial Fibrillation epidemiology, Heart Atria physiopathology, Heart Rate physiology, Risk Assessment methods, Stroke epidemiology
Abstract

Self-terminating atrial arrhythmias are commonly detected on continuous rhythm monitoring, e.g. by pacemakers or defibrillators. It is unclear whether the presence of these arrhythmias has therapeutic consequences. We sought to summarize evidence on the prevalence of atrial high-rate episodes (AHREs) and their impact on risk of stroke. We performed a comprehensive, tabulated review of published literature on the prevalence of AHRE. In patients with AHRE, but without atrial fibrillation (AF), we reviewed the stroke risk and the potential risk/benefit of oral anticoagulation. Atrial high-rate episodes are found in 10-30% of AF-free patients. Presence of AHRE slightly increases stroke risk (0.8% to 1%/year) compared with patients without AHRE. Atrial high-rate episode of longer duration (e.g. those >24 h) could be associated with a higher stroke risk. Oral anticoagulation has the potential to reduce stroke risk in patients with AHRE but is associated with a rate of major bleeding of 2%/year. Oral anticoagulation is not effective in patients with heart failure or survivors of a stroke without AF. It remains unclear whether anticoagulation is effective and safe in patients with AHRE. Atrial high-rate episodes are common and confer a slight increase in stroke risk. There is true equipoise on the best way to reduce stroke risk in patients with AHRE. Two ongoing trials (NOAH-AFNET 6 and ARTESiA) will provide much-needed information on the effectiveness and safety of oral anticoagulation using non-vitamin K antagonist oral anticoagulants in patients with AHRE., (© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Published
2019
Full Text
View/download PDF

41. Rationale and design of the EU-CERT-ICD prospective study: comparative effectiveness of prophylactic ICD implantation.

Author

Zabel M, Sticherling C, Willems R, Lubinski A, Bauer A, Bergau L, Braunschweig F, Brugada J, Brusich S, Conen D, Cygankiewicz I, Flevari P, Taborsky M, Hansen J, Hasenfuß G, Hatala R, Huikuri HV, Iovev S, Kääb S, Kaliska G, Kasprzak JD, Lüthje L, Malik M, Novotny T, Pavlović N, Schmidt G, Shalganov T, Sritharan R, Schlögl S, Szavits Nossan J, Traykov V, Tuinenburg AE, Velchev V, Vos MA, Willich SN, Friede T, Svendsen JH, and Merkely B

Subjects
Cardiomyopathy, Dilated complications, Cardiomyopathy, Dilated mortality, Death, Sudden, Cardiac epidemiology, Death, Sudden, Cardiac etiology, Electrocardiography, Europe epidemiology, Follow-Up Studies, Humans, Patient Selection, Prospective Studies, Quality of Life, Survival Rate trends, Treatment Outcome, Cardiomyopathy, Dilated therapy, Death, Sudden, Cardiac prevention & control, Defibrillators, Implantable, Primary Prevention methods, Risk Assessment
Abstract

Aims: The clinical effectiveness of primary prevention implantable cardioverter defibrillator (ICD) therapy is under debate. The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators (EU-CERT-ICD) aims to assess its current clinical value., Methods and Results: The EU-CERT-ICD is a prospective investigator-initiated non-randomized, controlled, multicentre observational cohort study performed in 44 centres across 15 European Union countries. We will recruit 2250 patients with ischaemic or dilated cardiomyopathy and a guideline indication for primary prophylactic ICD implantation. This sample will include 1500 patients at their first ICD implantation and 750 patients who did not receive a primary prevention ICD despite having an indication for it (non-randomized control group). The primary endpoint is all-cause mortality; the co-primary endpoint in ICD patients is time to first appropriate shock. Secondary endpoints include sudden cardiac death, first inappropriate shock, any ICD shock, arrhythmogenic syncope, revision procedures, quality of life, and cost-effectiveness. At baseline (and prior to ICD implantation if applicable), all patients undergo 12-lead electrocardiogram (ECG) and Holter ECG analysis using multiple advanced methods for risk stratification as well as detailed documentation of clinical characteristics and laboratory values. Genetic biobanking is also organized. As of August 2018, baseline data of 2265 patients are complete. All subjects will be followed for up to 4.5 years., Conclusions: The EU-CERT-ICD study will provide a necessary update about clinical effectiveness of primary prophylactic ICD implantation. This study also aims for improved risk stratification and patient selection using clinical and ECG risk markers., (© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results